10 February 2022>: Clinical Research
A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban
Zi-Yan Wang 1ABC , You-Dong Wan 2CDEF , Xian-Zhi Liu 1EFG , Hao Wang 1AD , Guang-Yi Jiang 1ABF , Bo Yang 1ABCDEFG*DOI: 10.12659/MSM.934341
Med Sci Monit 2022; 28:e934341
Table 2 Comparison of primary endpoint between rivaroxaban and placebo groups.
Parameter | Rivaroxaban (n=47) | Placebo (n=47) | P value |
---|---|---|---|
Venous thromboembolism | 1 (2.1%) | 10 (21.3%) | 0.008* |
Distal deep-vein thrombosis | 1 (2.1%) | 6 (12.8%) | 0.11* |
Proximal deep-vein thrombosis | 0 | 3 (6.4%) | |
Pulmonary embolism | 0 | 1 (2.1%) | |
Symptomatic deep-vein thromboses | 0 | 2 (4.2%) | |
* Fisher’s exact probability test was used for analysis. |